TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00336791
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FAC Chemotherapy: 50 mg/m\^2 IV on day 1 over 72 hour continuous infusion or IV bolus.
Study: NCT02849860
Drug: IDP-121 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotion
Study: NCT02799784
Drug: TIO/OLO
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIO/OLO inhalation spray will be supplied as an inhalation spray delivered using a RESPIMAT inhaler. Each actuation from the RESPIMAT inhaler delivers 3.124 mcg tiotropium bromide monohydrate (equivalent to 2.5 mcg tiotropium) and 2.736 mcg olodaterol hydrochloride (equivalent to 2.5 mcg olodaterol)
Study: NCT01291914
Drug: Placebo 1 (Carrier)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intra-articular injection
Study: NCT01291914
Drug: Placebo 2 (Diluent)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intra-articular injection
Study: NCT02644629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.9%, Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)
Study: NCT04594226
Drug: Medication
Normalized name: Acne Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage of gabapentin starts from 100mg Tid. 100mg-300mg can be increased every 3-7 days and taken in three doses, but the total amount is not more than 1800mg/day. The dosage of gabapentin will be adjusted according to the patient's condition until his pain is effectively controlled. After maintaining the medication for two weeks, the dosage can be gradually reduced and 100mg can be reduced every 3-7 days.
Study: NCT02000336
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To compare two standard p.o. GC starting dosages and the non-use of GCs in the treatment of patients with early active RA on the background of the established 'anchor' therapy with methotrexate (MTX).
Study: NCT02000336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00674570
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 25 mg/oral one hour prior to extinction task
Study: NCT00674570
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One hour prior to extinction task
Study: NCT01725269
Drug: AIR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: All doses specified are the amount loaded into the I-neb AAD System nebulizer.
Study: NCT04077957
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 10mg per week will be the background therapy in participants in Group 1. Experimental.
Study: NCT01551602
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple administration of placebo AK159
Study: NCT01499225
Drug: YH14642 500mg Tab
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH14642 500mg per day(once a day)
Study: NCT01499225
Drug: YH14642 500mg Tab
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH14642 1000mg per day(twice a day)
Study: NCT01499225
Drug: YH14642 500mg Tab
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH14642 2000mg per day(three times a day)
Study: NCT01499225
Drug: INSADOL[Zea mays L. extract] 35mg Tab
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[Initiation dose : 4weeks after administraion\] INSADOL\[Zea mays L. extract\] 210mg TAB per day~\[Maintain dose : Between 4weeks and 8weeks after administraion\] INSADOL\[Zea mays L. extract\] 105mg TAB per day~\[Maintain dose : Between 8weeks and 12weeks after administraion\] INSADOL\[Zea mays L. extract\] 105mg TAB per day
Study: NCT01499225
Drug: DENTISTA[Doxycycline hyclate] 20mg Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: DENTISTA\[Doxycycline hyclate\] Cap 40mg per day
Study: NCT01499225
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04033250
Drug: Sodium Picosulfate / Magnesium Oxide / Citric Acid in two split doses + one dose of polyethylene glycol + two Bisacodyl tablets day before the procedure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel preparation
Study: NCT02130804
Drug: Salsalate (4 g/day)
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally twice daily
Study: NCT02130804
Drug: Placebo (4 g/day)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally twice daily
Study: NCT03080350
Drug: Fentanyl sublingual
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl sublingual
Study: NCT03080350
Drug: Fentanyl ev
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl ev
Study: NCT03080350
Drug: Placebo sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sublingual
Study: NCT03080350
Drug: Placebo ev
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - NaCL 0,9% ev
Study: NCT00076752
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Priming regimen: 2000 mg/m\^2 intravenous infusion over 2 hours, day 2. Conditioning and transplant regimen: 1200 mg/m\^2 day intravenous infusion daily, 4 days (-6, -5, -4, -3).
Study: NCT04108104
Drug: Alpress LP
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-month treatment
Study: NCT02817516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-828 placebo-matching solution.
Study: NCT00832442
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: as determined by individual study
Study: NCT03472456
Drug: Implementation of a pulp medication in compliance with the dental emergency management protocol: articaïne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation of a pulp medication in compliance with the dental emergency management protocol: articaïne
Study: NCT03727152
Drug: generic single tablet TAF/FTC/DTG
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-infected adults who are virologically suppressed and on protease inhibitor/ritonavir are switched to generic single tablet regimen of tenofovir alafenamide/emtricitibine/dolutegravir
Study: NCT02557932
Drug: Standard triple therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30mg, 2 times a day + Clarithromycin 500mg, 2 times a day + Amoxicillin 1000mg, 2 times a day for 7 days
Study: NCT02426723
Drug: Phase 1a: CWP232291
Approvals — FDA: no, EMA: no, PMDA: no
Description: CWP232291 administered alone twice weekly every 4 weeks.
Study: NCT04026165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily
Study: NCT02637895
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill matching Vortioxetine.
Study: NCT02360319
Drug: Any FDA approved antipsychotic agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigators are free to choose the most appropriate treatment for their clients
Study: NCT03471169
Drug: Undesirable TEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Don't change the type and dose of antithrombotic therapy and obtain undesirable TEG results. Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol.
Study: NCT01363752
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. and oral
Study: NCT00284778
Drug: Alimta®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03562611
Drug: Nalbuphine and Flurbiprofen Axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine and Flurbiprofen Axetil administration during surgery
Study: NCT03645746
Drug: REGN5069
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGN5069 will be administered by IV infusion or SC injection
Study: NCT03645746
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching REGN5069
Study: NCT01675570
Drug: RX-10045
Normalized name: BARRIER,SENSURA COLOPLAST #10045
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of RX-10045 ophthalmic solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
Study: NCT02500147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo pill per day for one week and then two placebo pills per day for the remainder of the six months
Study: NCT04448561
Drug: ASP8082
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT04448561
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02976779
Drug: OWC Control Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Cream without active ingredients
Study: NCT00782184
Drug: ezetimibe/simvastatin 10/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin 10/40 tablet once daily for 6 weeks.
Study: NCT03830684
Drug: blank control 0mg
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 placebo per time, three times a day
Study: NCT04387630
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone 60 mg three times daily.
Study: NCT01302444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 12 weeks
Study: NCT02967289
Drug: Folfox Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: every 14 days, 12 cycles, 24 weeks, new cycle beginning on day 15: oxaliplatin (Eloxatin®) 85 mg/m² on D1, IV infusion over 2 hours, followed by folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid) IV infusion over 2 hours 5-FU 2400 mg/m²/h IV continuous infusion over 46 hours starting at the end of folinic acid infusion
Study: NCT02360631
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education counseling will be provided to all participants.
Study: NCT00857168
Drug: Testosterone MD-Lotion
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02689869
Drug: GA 101
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.
Study: NCT01606527
Drug: Ibuprofen 600mg orally three times daily
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ibuprofen is taken 600mg orally three times daily
Study: NCT02912260
Drug: MGL-3196
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02912260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01614782
Drug: MK-5823
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5823 administered subcutaneously (doses ranging from 0.35 mg to 2.8 mg) once daily for 3 weeks. Doses may be adjusted downward based on safety, tolerability, and/or pharmacokinetic data. The decision to dose escalate will be based on accrued safety/tolerability data at the prior dose level.~In each arm, 6 participants will be randomized to receive study drug and 2 participants will be randomized to receive placebo.
Study: NCT01889186
Drug: ABT-199 (Main Cohort)
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received a test dose of ABT-199 of ≤ 20 mg on Week 1 Day 1 of the Lead-In Period. For those with significant electrolyte and/or lymphocyte changes within 24 hours of the first dose, the 20 mg dose was maintained for 7 days with escalation to 50 mg on Week 2 Day 1. If none of the electrolyte and/or lymphocyte changes occurred within 24 hours from ABT-199 20 mg dose administration, the participant was dose-escalated to 50 mg on Week 1 Day 2. After the first dose of 50 mg, if no laboratory abnormalities occurred, the participant remained on the 50 mg dose through Week 1. After receiving the 50 mg dose for approximately 1 week (6 to 7 days), the following dose escalation proceeded with weekly increases in dose: → 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose), as tolerated.
Study: NCT01889186
Drug: ABT-199 (Safety Expansion Cohort)
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received an initial dose of ABT-199 of 20 mg on Week 1 Day 1 of the Lead-In Period. If one or more electrolyte changes (from the 0 hr measurement prior to dosing) suggestive of laboratory tumor lysis syndrome (LTLS) or clinical TLS (CTLS) occurred within 24 hours of the 20 mg dose, no additional doses were administered until resolution. Upon resolution of laboratory abnormalities, the 20 mg dose was continued through Week 1. If no significant findings suggestive of clinical or laboratory TLS occurred within 24 hours, the 20 mg dose was continued through Week 1 Day 7, and escalated to a dose of 50 mg on Week 2 Day 1. Those who had drug interruptions may have been allowed to escalate to and be maintained at 50 mg for 1 week after they had been on a 20 mg dose for at least 1 week (5 - 7 days). After a week at 50 mg, weekly dose escalations were implemented as follows: 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose) as tolerated.
Study: NCT03575299
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with anti-tuberculosis drugs throughout the entire process of the study.
Study: NCT02103959
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow bolus IV administration of PBS
Study: NCT02822573
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be asked to take one tablet of matching placebo daily for 6 weeks followed by two tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
Study: NCT03891862
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-active dosage form
Study: NCT02855359
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Study: NCT02855359
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Study: NCT00262470
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin 25-50 mg PO x 1 dose
Study: NCT01023256
Drug: MOR103
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOR103 0.3 mg/kg or placebo iv x 4 doses
Study: NCT01023256
Drug: MOR103
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOR103 1.0 mg/kg or placebo iv x 4 doses
Study: NCT01023256
Drug: MOR103
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOR103 1.5 mg/kg or placebo iv x 4 doses
Study: NCT01971164
Drug: JTZ-951
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive JTZ-951 or Placebo
Study: NCT01245543
Drug: AC480IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC480IV will be administered as an infusion using a dose escalation design.
Study: NCT04430842
Drug: QBS10072S
Approvals — FDA: no, EMA: no, PMDA: no
Description: QBS10072S targets cancers with high LAT1 expression.
Study: NCT02197286
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of a single gelatin placebo capsule.
Study: NCT03589326
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate IV infusion.
Study: NCT01971164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02288091
Drug: Inosine
Normalized name: Inosine
DrugBank: Inosine (DB04335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twenty-five eligible subjects will receive inosine for 12 weeks (administered in the form of 500 mg capsules, 1 to 6 capsules a day for a total daily dose of up to 3 gm). The dose of inosine will be titrated to target urate levels of 7-8 mg/dL based on urate level measurement that will occur at Week 2, Week 4, Week 6, and Week 9 after Baseline.
Study: NCT00987870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03435952
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting on Day 15, participant takes Doxycycline by mouth 2 times a day for the rest of participant's life to lower the risk of further growth of Clostridium novyi-NT
Study: NCT04537910
Drug: LY3819253
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT04537910
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT02349919
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 4 weeks
Study: NCT01658124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03596723
Drug: KPI-121 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: eye drops
Study: NCT03596723
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eye drops
Study: NCT02569437
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline (200 mg PO X 1 dose on Day 1, then 100 mg PO daily) for Day 2-20
Study: NCT00438737
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00438737
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00792688
Drug: GLYC-101 Gel (0.1%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
Study: NCT00792688
Drug: GLYC-101 Gel (1.0%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
Study: NCT00792688
Drug: GLYC-101 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
Study: NCT03651427
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induced hypogonadism and re-institution of CSHT
Study: NCT02320773
Drug: Betmiga®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02091479
Drug: UFH Early group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).~Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily).
Study: NCT02091479
Drug: UFH Late group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).~Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily).
Study: NCT04074590
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule for oral use
Study: NCT00908089
Drug: Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and placebo infusion during first 6 months
Study: NCT00199797
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin was administered at a dose of 200mg/m2 on day 2 and day 3 of every 2 week regimen.
Study: NCT00660075
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 6 weeks
Study: NCT00435279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01265602
Drug: LAS41007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
Study: NCT01265602
Drug: LASW1510
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
Study: NCT03892577
Drug: Precision oncology including targeted therapy and immunotherapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic regimens are based on the clinicopathological features, genomic alterations, advices from multidisciplinary tumor board and willings from patients.
Study: NCT01953874
Drug: Optimized Medical Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
Study: NCT00166257
Drug: Medical antitrhombotic treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice: Anticoagulation to INR 2.0 - 3.0 OR Aspirin 100-325 mg/d OR Clopidogrel 75-150 mg/d
Study: NCT01393509
Drug: PU-H71
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PU-H71 will be administered as an intravenous infusion over 1 hour two times a week on a 2 week on and 1 week off (Q21 day) schedule with a starting dose of 10 mg/m2. A Cycle on study will be defined as 21 days. The same schedule of administration will be used for all patients in this Phase I trial, and a MCRM (modified continual reassessment method)design will be employed. The MPN expansion may explore different dosing schedules.
Study: NCT00006398
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no